100% Quality Guarantee
PhD-Level Technical Support
Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-Cav3.1 Monoclonal Antibody, Clone N178A/9 (STMA00120). Tissue: Neuroblastoma cells (SH-SY5Y). Species: Human. Fixation: 4% PFA for 15 min. Primary Antibody: Mouse Anti-Cav3.1 Monoclonal Antibody (STMA00120) at 1:50 for overnight at 4°C with slow rocking. Secondary Antibody: AlexaFluor 488 at 1:1000 for 1 hour at RT.
Key Features

Anti-Cav3.1 Antibody [N178A/9 (Formerly sold as S178A-9)]

SKU STMA00120
Antibody Type Monoclonal
Applications WB
Applications IHC
Applications ICC/IF
Reactivity Human
Reactivity Mouse
Reactivity Rat
Host Species Mouse
Isotype IgG1
$854

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Cav3.1 Antibody [N178A/9 (Formerly sold as S178A-9)]

Cav3.1 Antibody [N178A/9 (Formerly sold as S178A-9)] is a mouse monoclonal antibody directed against Cav3.1, offered by Assay Genie for research applications. Reported applications include WB, IHC and ICC/IF. Reported reactivity: Human, Mouse and Rat. Supplied as IgG1, purified by Protein G.

Cav3.1, encoded by the CACNA1G gene, is a low-voltage-activated T-type calcium channel that plays a pivotal role in regulating neuronal excitability and rhythmic firing. Widely expressed across tissues, Cav3.1 is particularly important in the central nervous system, where it contributes to burst firing and oscillatory activity in thalamic and cortical neurons. In the heart, it may also participate in pacemaker currents, highlighting its physiological versatility. In the brain, Cav3.1 channels are considered secondary pacemakers, modulating sleep-wake cycles, sensory processing, and synaptic integration. Dysregulation of Cav3.1 activity has been implicated in a range of neurological and neurodegenerative disorders, including epilepsy, Parkinson’s disease, and essential tremor. Altered T-type calcium channel function may also contribute to cognitive decline and neuroinflammation, positioning Cav3.1 as a potential therapeutic target in age-related neurodegeneration. Pharmacological blockers of T-type calcium channels, including Cav3.1, are already used clinically as antihypertensives and antiepileptics. Emerging evidence suggests these channels may also mediate the effects of certain anesthetics and antipsychotics, further underscoring their relevance in neuropharmacology. Despite their clinical significance, many aspects of Cav3.1’s cellular localization, in vivo function, and disease-specific roles remain underexplored. Advancing our understanding of Cav3.1 could unlock new strategies for modulating calcium signaling in neurodegenerative disease. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose